ALKS News & Analysis

Alkermes (ALKS) Stock Price Target Raised to $53 by Mizuho

Mizuho increased its price target for Alkermes (ALKS) to $53, attributing the change to improved confidence in the company's drug pipeline. This revision reflects optimism regarding potential therapeutic advancements. The adjustment is significant for investors monitoring ALKS, as price targets can influence market sentiment and trading decisions. Increased confidence in drug development may correlate with higher stock valuations moving forward.